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OBJECTIVES: Estimate prevalence of and factors associated
with prolonged clinical inertia among patients with Type 2 dia-
betes. METHODS: Using 2000–2005 automated clinical and
pharmacy data, we identiﬁed an insured cohort of patients with
diabetes at the time of oral monotherapy initiation (N = 5082).
Actuarial methods were used to estimate time to prolonged
inertia (deﬁned as 2 HbA1c values over 8% at least 90 days
apart, not yet dispensed insulin with no medication change in the
preceding 90 days). Among the subset facing prolonged inertia
(N = 1391), actuarial methods and Cox regression were used to
estimate time to and factors associated with medication intensi-
ﬁcation (dose change, class change, or class addition) or control
(HbA1c < 7%). RESULTS: At inception, mean age was 60.1
years, 48% were female and 37% African American. Mean
HbA1c was 8.8% and 97% were dispensed Sulfonylurea or
Metformin. 8% of patients faced prolonged inertia within 1 year,
17% within 2 years, 24% within 3 years and 30% within 4
years. At the time of prolonged inertia, 55% remained on mono-
therapy, 25% were on combination oral therapy, and 20% had
no medication on hand. Mean time to medication intensiﬁcation/
control was 7.3 months, with 27% having neither within 1 year.
African American patients (hazard ratio = 0.83, 95% CI = 0.72–
0.96), those with no anti-diabetic medication dispensing (0.66,
0.54–0.80) or combination oral therapy dispensing (0.83, 0.71–
0.97) faced longer delays. Increased delays were also associated
with each additional dollar of drug co-payment (0.95, 0.93–
0.98). Shortened delays were associated with each additional
HbA1c percent (1.11, 1.08–1.15) and each additional visit to
emergency department (1.27, 1.02–1.59), primary care (1.80,
1.57–2.15) and endocrinology (1.95, 1.36–2.78). CONCLU-
SION: Patients with Type 2 diabetes facing prolonged inertia are
at risk of further delays in appropriate management. Our ﬁnd-
ings suggest the presence of multi-level barriers to appropriate
care. Increased contact with the health care system may mitigate
risk.
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OBJECTIVES: The increasing prevalence of overweight and
obesity in US means increasing cost of treating cardiovascular
and other life threatening diseases. This is particularly relevant
to people with type 2 diabetes (T2D) of whom over 80% are
overweight or obese. Limited data exist on the impact of over-
weight and obesity on health care cost for the people with
T2D. The objective was to identify the relations between health
care cost and BMI for people with T2D. METHODS: Genera-
lised Linear Models (GLM) were performed linking demo-
graphic variables (age, gender, ethnicity, BMI, HbA1c) and
annual cost of medical resources (drugs, hospitalisation and
visits to health professionals (PCP’s, cardiologist, diabetes spe-
cialist, diabetes nurse, other doctor/nurse)). Data was based on
643 patients diagnosed with T2D, aged between 35 to 64 years
and a BMI  20 kg/m2 (based on physician reported height
and weight) from the Adelphi Metabolic Syndrome Disease
Speciﬁc Programme in 2006. People were stratiﬁed according to
their BMI; normal/overweight (20–29.99 kg/m2; n = 110),
obese (30–34.99 kg/m2; n = 178); very obese (35–39.99 kg/m2;
n = 170) and morbidly obese (>39.99 kg/m2; n = 185).
RESULTS: The GLM analyses showed a signiﬁcant impact on
health care cost determined by age, BMI and HbA1c. This
means that the major signiﬁcant contributors to the short term
health care cost of type 2 diabetes are the people’s age, BMI
group and HbA1c level. Compared with a BMI between
20–29.99 kg/m2 moving to the BMI group 30–34.99 kg/m2,
35–39.99 kg/m2, and >39.99 kg/m2 results in an increase in
cost of $363 (p = 0.06), $553.7 (p < 0.05), and $674.4
(p < 0.05) per year, respectively. CONCLUSION: These ﬁnd-
ings suggest that health care costs of type 2 diabetics are posi-
tively correlated with age, BMI and HbA1c level. The impact of
obesity on health care cost is particularly evident in people with
T2D in the high obesity groups.
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OBJECTIVES: Continous subcutaneous insulin infusion (CSII)
therapy has become a frequently used and safe treatment in
adolescents and children with type 1 diabetes. Despite this, many
patients either don’t consider CSII as a potential therapy or
decide to discontinue use of CSII, especially during adolescence.
Aim of the study was to determine attitudes towards CSII and
factors related to it’s discontinuation. METHODS: Onto com-
prehensive literature research we surveyed attitudes towards CSII
in three groups—patients who are still using the CSII (A),
patients who stopped CSII (B) and patients who never applied
CSII (C). Questionnaire speciﬁcations and items were developed
with aid of a peergroup which consisted of 4 A-patients, 2
B-patients, and 2 C-patients. The questionnaire included nearly
60 attitude items measured on a four point- Likert-type scale
(1 = highest, 4 lowest). After pretest probands (inclusion criteria:
between 15 and 25 years) were recruited by their attending
physicians. RESULTS: In total, 88 patients from 11 diabetes
centers (contacted: 71 centers) were surveyed. From these 88
patients 46 patients belonged to group A, 20 to B and 22 to C.
A-patients were signiﬁcantly (p < 0.001) younger (9 years) than
patients from the other groups (B: 11 years, C: 15 years), respec-
tively at moment of ﬁrst diabetes education. Main reasons for
refusing CSII were the permanent catheter (1.4  0.6) and CSII
annoys during sport (1.8  0.9), CSII is unhandly (1.8  1.0).
Reasons for discontinuation were similar: CSII annoys in
summer (1.5  0.9), catheter is getting lost during sport
(1.7  0.9) and CSII annoys during sport (1.9  1.2). CON-
CLUSION: There are no main differences between attitudes
towards CSII in the three groups. Patients aren’t in doubt about
reliability of CSII and main reasons for not trying or discontinu-
ating CSII are associated with the catheter at physical activity.
Decision is mainly physician driven.
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